Episode 514: Artificial Intelligence in Cancer Drug Development
Jul 20, 202640m
Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.
Loading…
Loading…
Hosted by Unknown Host · 🇺🇸 US · EN · 479 episodes
Established thought leaders with verified media credentials.
Broadcasting the latest developments in GU cancerHosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer CenterTom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London
Unknown Host hosts The Uromigos, a health show with 479 episodes published.
Travis Zack, CMO of Open Evidence, joins Brian and Tom to discuss the emergence of AI across the spectrum on cancer, drug development and application of data.
Bishoy Faltas joins Brian and Tom to discuss his IIT in bladder cancer. The intended discussion of the trials turned into an insightful discussion on the challenges and learning opportunities of IITs.
In our final episode recorded at APCCC, Louise Emmett joins us to discuss clinical results and mechanisms of PSMA upregulation by enzalutamide.
Tanya Dorff joins Tom and Brian to discuss her ASCO 2026 data on a novel dual targeting ADC in prostate cancer. The broader scope of ADC development in prostate cancer is discussed with a focus on cytopenia toxicity and
This comprehensive podcast covers the latest advances in prostate, bladder, and kidney cancers from ASCO 2026, including new therapies, trial data, and practice-changing insights. Brian, Tom and Silke analyze recent stud
Mary Ellen Taplin joins us on the heels of her ASCO 2026 Plenary presentation with this exciting phase 3 data certain to generate discussion about the landscape of high risk prostate cancer.
Neeraj Aggarwal joins the show to discuss the phase 3 TALAPRO-3 trial of talazoparib and enzlautamide in metastatic hormone-sensitive prostate cancer, focusing on trial design, efficacy, safety, and genetic subsets.
This panel discussion podcast with Brian, Tom, Peter O'Donnell and Elizabeth Nally explores the complexities of measuring quality of life in cancer clinical trials, highlighting recent data, patient perspectives, and inn
James Larkin joins us to discuss the durvalumab monotherapy arm from RAMPART and we discuss the role of CTLA-4 inhibition broadly and how these data contribute to the adjuvant RCC landscape.
This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts di
This session features expert Michael Morris discussing radioligand therapy, adaptive dosing, retreatment strategies, and the latest insights in prostate cancer treatment. Gain a deep understanding of current practices, c
Silke joins Brian and Tom to discuss what to look for in GU cancers at ASCO 2026
In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of d
Chuck Ryan from MSKCC joins us in Lugano for the final podcast from APCCC to talk about the ever-evolving space of BCR in prostate cancer.
Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer a
This APCCC podcast with Elena Castro features a detailed discussion on recent advances and ongoing debates in the treatment of castrate resistant prostate cancer (CRPC), including the placement of lutetium, biomarker-dri
This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-ri
Rob Jones joins us in Lugano at the APCCC Meeting to discuss areas of consensus and controversy in the mHSPC landscape including de-escalation strategies.
This episode with Piet Ost covers the latest insights from the APCCC conference in Lugano, focusing on locally advanced prostate cancer, biochemical relapse, and the role of PSMA PET imaging and biomarkers in treatment d
Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
The Uromigos has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their health audience.
The Uromigos is hosted by Unknown Host. The show is categorised under health (fitness) and has published 479 episodes.
The Uromigos has published 479 episodes.
The Uromigos regularly covers health, fitness, medicine. It sits in the health category, with a fitness focus.
The Uromigos is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
The Uromigos hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of The Uromigos average 35 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates The Uromigos's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 6 days ago.